BRPI0608309A2 - administração intranasal de agentes ativos ao sistema nervoso central - Google Patents
administração intranasal de agentes ativos ao sistema nervoso centralInfo
- Publication number
- BRPI0608309A2 BRPI0608309A2 BRPI0608309-9A BRPI0608309A BRPI0608309A2 BR PI0608309 A2 BRPI0608309 A2 BR PI0608309A2 BR PI0608309 A BRPI0608309 A BR PI0608309A BR PI0608309 A2 BRPI0608309 A2 BR PI0608309A2
- Authority
- BR
- Brazil
- Prior art keywords
- nervous system
- central nervous
- intranasal administration
- active agents
- polypeptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/086—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being alphaMSH, alpha melanocyte stimulating hormone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Abstract
ADMINISTRAçãO INTRANASAL DE AGENTES ATIVOS AO SISTEMA NERVOSO CENTRAL. é fornecido um método para liberar um polipeptídeo para o sistema nervosa central de um mamífero. O método envolve ligar o polipeptideo a um anticorpo ou um fragmento de anticorpo e administrar o polipeptideo de fusão intranasalmente, para a liberação para o sistema nervosa central. São também fornecidos métodos de tratamento, onde uma quantidade terapeuticamente eficaz da composição é liberada para a cavidade nasal de um mamífero.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65580905P | 2005-02-23 | 2005-02-23 | |
PCT/US2006/003110 WO2006091332A2 (en) | 2005-02-23 | 2006-01-27 | Intranasal administration of active agents to the central nervous system |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0608309A2 true BRPI0608309A2 (pt) | 2009-12-08 |
Family
ID=36821878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0608309-9A BRPI0608309A2 (pt) | 2005-02-23 | 2006-01-27 | administração intranasal de agentes ativos ao sistema nervoso central |
Country Status (12)
Country | Link |
---|---|
US (1) | US20060188496A1 (pt) |
EP (1) | EP1853288A2 (pt) |
JP (1) | JP2008531560A (pt) |
KR (1) | KR20070110087A (pt) |
CN (1) | CN101184499B (pt) |
AU (1) | AU2006217027A1 (pt) |
BR (1) | BRPI0608309A2 (pt) |
CA (1) | CA2598666A1 (pt) |
HK (1) | HK1122723A1 (pt) |
MX (1) | MX2007010244A (pt) |
NZ (1) | NZ581205A (pt) |
WO (1) | WO2006091332A2 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090136505A1 (en) * | 2005-02-23 | 2009-05-28 | Johanna Bentz | Intranasal Administration of Active Agents to the Central Nervous System |
EP2179741B1 (en) | 2005-08-26 | 2014-10-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administraton of oxytocin |
US7790671B2 (en) | 2005-10-07 | 2010-09-07 | Codman & Shurtleff, Inc. | Implantable pump for protein delivery for obesity control by drug infusion into the brain |
US20100129354A1 (en) * | 2006-10-27 | 2010-05-27 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
DE102007052380A1 (de) * | 2007-10-31 | 2009-05-07 | Bitop Ag | Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten |
DE102008039231A1 (de) | 2008-08-22 | 2010-02-25 | Bitop Ag | Verwendung von Glucosylglycerol |
US8609088B2 (en) | 2011-05-10 | 2013-12-17 | Regents Of The University Of Minnesota | Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases |
PL2961426T3 (pl) | 2013-02-26 | 2020-02-28 | Baxalta GmbH | Leczenie zaburzeń ośrodkowego układu nerwowego przez donosowe podawanie immunoglobuliny g |
WO2014176360A1 (en) * | 2013-04-23 | 2014-10-30 | Board Of Regents, The University Of Texas System | Methods for reducing acute axonal injury |
HUE044737T2 (hu) | 2013-05-06 | 2019-11-28 | Baxalta Inc | Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel |
EP3804811A1 (en) * | 2013-05-13 | 2021-04-14 | Icahn School of Medicine at Mount Sinai | Treatment of mood and anxiety disorders |
KR20240093939A (ko) | 2013-05-15 | 2024-06-24 | 리젠츠 오브 더 유니버시티 오브 미네소타 | 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달 |
FI3242676T3 (fi) | 2015-01-07 | 2023-11-07 | TONIX Pharmaceuticals Holding Corp | Magnesiumipitoisia oksitosiiniformulaatioita ja käyttömenetelmiä |
EP3377089B1 (en) * | 2015-11-18 | 2020-04-08 | Herantis Pharma Plc | Compositions comprising cdnf for use in the intranasal treatment of central nervous system diseases |
BR112018071156A2 (pt) | 2016-04-15 | 2019-03-12 | The Trustees Of The University Of Pennsylvania | terapia de gene para tratar mucopolissacaridose tipo ii |
SG11201901272WA (en) * | 2016-08-14 | 2019-03-28 | Univ Ramot | Mesenchymal cell-derived exosomes to treat neurological disorders |
EP3684938A1 (en) | 2017-09-22 | 2020-07-29 | The Trustees of the University of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
WO2020163815A1 (en) * | 2019-02-07 | 2020-08-13 | Innomed Technologies, Inc. | Ivig treatments for bell's palsy |
WO2020177627A1 (zh) * | 2019-03-02 | 2020-09-10 | 上海一宸医药科技有限公司 | 一种双特异抗体 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4476116A (en) * | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5856298A (en) * | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
GB9020544D0 (en) * | 1990-09-20 | 1990-10-31 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5830853A (en) * | 1994-06-23 | 1998-11-03 | Astra Aktiebolag | Systemic administration of a therapeutic preparation |
US5897858A (en) * | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6750324B1 (en) * | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
US7273618B2 (en) * | 1998-12-09 | 2007-09-25 | Chiron Corporation | Method for administering agents to the central nervous system |
JP2002531489A (ja) * | 1998-12-09 | 2002-09-24 | カイロン コーポレイション | 中枢神経系への神経栄養剤の投与 |
EP3124067A3 (en) * | 1999-03-03 | 2017-05-24 | Optinose AS | Nasal delivery device |
CA2380331C (en) * | 1999-08-09 | 2012-11-20 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
US6824780B1 (en) * | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
CA2490411A1 (en) * | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
US6734427B1 (en) * | 2003-02-14 | 2004-05-11 | United Microelectronics Corp. | TEM/SEM sample preparation |
-
2006
- 2006-01-27 WO PCT/US2006/003110 patent/WO2006091332A2/en active Application Filing
- 2006-01-27 CA CA002598666A patent/CA2598666A1/en not_active Abandoned
- 2006-01-27 MX MX2007010244A patent/MX2007010244A/es unknown
- 2006-01-27 AU AU2006217027A patent/AU2006217027A1/en not_active Abandoned
- 2006-01-27 KR KR1020077021057A patent/KR20070110087A/ko not_active Application Discontinuation
- 2006-01-27 CN CN2006800136679A patent/CN101184499B/zh not_active Expired - Fee Related
- 2006-01-27 BR BRPI0608309-9A patent/BRPI0608309A2/pt not_active IP Right Cessation
- 2006-01-27 EP EP06719803A patent/EP1853288A2/en not_active Withdrawn
- 2006-01-27 US US11/342,058 patent/US20060188496A1/en not_active Abandoned
- 2006-01-27 NZ NZ581205A patent/NZ581205A/en not_active IP Right Cessation
- 2006-01-27 JP JP2007557028A patent/JP2008531560A/ja active Pending
-
2008
- 2008-11-19 HK HK08112641.0A patent/HK1122723A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN101184499A (zh) | 2008-05-21 |
MX2007010244A (es) | 2008-03-10 |
WO2006091332A2 (en) | 2006-08-31 |
HK1122723A1 (en) | 2009-05-29 |
CA2598666A1 (en) | 2006-08-31 |
KR20070110087A (ko) | 2007-11-15 |
US20060188496A1 (en) | 2006-08-24 |
CN101184499B (zh) | 2012-03-28 |
EP1853288A2 (en) | 2007-11-14 |
AU2006217027A1 (en) | 2006-08-31 |
JP2008531560A (ja) | 2008-08-14 |
WO2006091332A3 (en) | 2006-11-16 |
NZ581205A (en) | 2011-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0608309A2 (pt) | administração intranasal de agentes ativos ao sistema nervoso central | |
CO2020011068A2 (es) | Métodos y composiciones para la administración de proteínas terapéuticas | |
WO2009058957A3 (en) | Intranasal administration of active agents to the central nervous system | |
GB201201314D0 (en) | Composition | |
EA201000211A1 (ru) | Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения | |
BRPI0922789A2 (pt) | peptídeo de ligação de albumina intermediador para reconhecimento de doença | |
EA201001204A1 (ru) | Методы и композиции, в которых применяют слитые полипептиды klotho-fgf | |
WO2006015259A3 (en) | Compounds and compositions as modulators of steroid hormone nuclear receptors | |
EP4276180A3 (en) | Clostridium histolyticum enzyme | |
ECSP10010439A (es) | Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina | |
NO20082510L (no) | En fremgangsmate for konsentrasjon av et polypeptid | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
MX2009002893A (es) | Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap). | |
PE20170938A1 (es) | Suministro al sistema nervioso central de agentes terapeuticos | |
EA200870185A1 (ru) | Комбинации ингибиторов ang2 и vegf | |
PE20181790A1 (es) | Metodos para tratar o prevenir trastornos relacionados con el colesterol | |
BRPI0510170B8 (pt) | composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto | |
JO2576B1 (en) | Antibodies | |
BRPI0713421A2 (pt) | Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero | |
AR060786A1 (es) | Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
ATE314062T1 (de) | Zusammensetzungen zur abgabe von cortisolantagonisten | |
WO2007134241A3 (en) | Nasal delivery of therapeutic agents using tight junction agonists | |
EP2279244A4 (en) | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | |
MX2008008413A (es) | Composicion farmaceutica para el tratamiento de las enfermedades de las uñas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15G | Petition not considered as such [chapter 15.7 patent gazette] |
Free format text: NAO CONHECIDA A PETICAO NO 046757/RJ DE 26/05/2010 EM VIRTUDE DO DISPOSTO NO ART. 219, INCISO II DA LPI. (QUANDO A PETICAO NAO APRESENTA FUNDAMENTACAO LEGAL) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2395 DE 29-11-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 38/34 (2006.01), A61K 9/00 (2006.01), A61K 47 |